Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Telix Pharmaceuticals Limited - American Depositary Shares (NQ:TLX)

11.10 +0.28 (+2.54%)
Streaming Delayed Price Updated: 2:06 PM EDT, Aug 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Telix Pharmaceuticals Limited - American Depositary Shares

< Previous 1 2 3 Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX
From Pomerantz LLP
Via GlobeNewswire
TLX Investors Have Opportunity to Join Telix Pharmaceuticals Limited Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Telix H1 2025 Results: Investor Webcast Notification
From Telix Pharmaceuticals Limited
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX
From Pomerantz LLP
Via GlobeNewswire
Securities Fraud Investigation Into Telix Pharmaceuticals Limited (TLX) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay & Murray LLP
Via Business Wire
Telix Pharmaceuticals Limited (TLX) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
Securities Fraud Investigation Into Telix Pharmaceuticals Limited (TLX) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Texas Instruments, SAP, Enphase Energy And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Why Vicor Shares Are Trading Higher By 39%; Here Are 20 Stocks Moving Premarket
Shares of Vicor Corporation (NASDAQ:VICR) rose sharply in pre-market trading after posting second-quarter results. 
Via Benzinga
Telix Reports $204M Revenue, Up 63% YOY
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Gozellix Receives Permanent HCPCS Code
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Telix Pharmaceuticals Trial Enter Critical Stage, Analyst Predicts Big Gains
Via Benzinga
This Primoris Services Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday
 
Via Benzinga
Illuccix Approved in U.S. for Patient Selection for Pre-Taxane RLT
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Telix Precision Medicine Announces AlFluor Radiochemistry Platform
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Telix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Telix Launches New Prostate Cancer Imaging Agent, Gozellix, in U.S.
From Telix Pharmaceuticals Limited
Via GlobeNewswire
This Excelerate Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
 
Via Benzinga
Telix Investor Day in New York City on June 11, 2025: Presenting KOLs
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Telix to Host Investor Day in New York City on June 11, 2025
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Telix's Illuccix PSMA-PET Imaging Agent Approved in France
New approval provides French hospitals and clinics with access to a proven PSMA-PET imaging agent 
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Telix Reports US$186M Q1 Revenue, Up 62% YOY
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Telix Pharmaceuticals Touts Encouraging Data From Investigational Radiation Therapy In Relapsed Brain Cancer Patients
Telix reports early Phase 2 data showing TLX101 improves survival in recurrent brain cancer patients, with no serious side effects observed. 
Via Benzinga
IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate
From Telix Pharmaceuticals Limited
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.